Leukemia
If it’s your first time on this website, please read the disclaimer section.
May 18 – May 25, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1/2a open-label study investigated CRISPR-Cas9 CD33-deleted allogeneic HCT (trem-cel) followed by gemtuzumab ozogamicin (GO) maintenance in 30 high-risk AML/MDS patients. All patients achieved neutrophil engraftment by day 28 (median 10 days, 95% CI: 9-10). GO maintenance was safely tolerated up to 2 mg/m² in 19 patients, with no prolonged high-grade cytopenias observed. This approach demonstrates safe, rapid engraftment and enables CD33-targeted maintenance without significant hematologic toxicity, offering a promising strategy for high-risk hematologic cancer patients.
10.1038/s41591-026-04362-1
Apr 27 – May 04, 2026
Adult T-Cell Leukemia/Lymphoma and Targeted Maternal Screening.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This population-based study analyzed US cancer registries (2005-2022) to estimate Adult T-cell leukemia/lymphoma (ATLL) incidence. It identified 3228 ATLL cases, finding non-Hispanic Caribbean-born US residents had an incidence rate of 14.1 per million, significantly higher than US/Canada-born populations (0.4 per million; IRR, 32.0), with rates peaking at 33.7 per million. Five-year survival was poor (23.8%), lowest among Caribbean-born individuals, highlighting a critical health disparity for this aggressive cancer. These findings identify early-life HTLV-1 infection as an actionable target for cancer prevention through maternal screening, with implications for reducing future ATLL burden.
10.1001/jamaoncol.2026.0859
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized, placebo-controlled trial evaluated whether prophylactic B-cell depletion with obinutuzumab could prevent corticosteroid-requiring chronic graft-versus-host disease (cGVHD) in 178 allogeneic transplant recipients. Obinutuzumab significantly reduced the 1-year incidence of steroid-requiring cGVHD to 13.3% compared to 35.2% in the placebo group (p=0.0005) and improved 2-year immunosuppression-free, relapse-free survival (48% vs. 34%). While the study focuses on a post-transplant complication, the findings are highly relevant for clinicians managing hematologic malignancies where cGVHD remains a major barrier to successful recovery. These results suggest that early B-cell depletion is an effective strategy for reducing morbidity and improving long-term outcomes in high-risk cancer patients undergoing transplantation.
10.1200/JCO-25-03104
Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase II study investigated the safety and efficacy of adding dilanubicel, an expanded progenitor cell product, to single-unit cord blood transplantation (CBT) in 28 patients with hematologic malignancies. All patients achieved neutrophil engraftment (median 18 days) and platelet engraftment (median 31 days), with no grade 3-4 acute or chronic GVHD observed. At a median 1.4-year follow-up, 27 patients remained alive and disease-free, demonstrating faster hematopoietic recovery and lower severe acute GVHD compared to standard CBT. These findings suggest dilanubicel improves the safety and outcomes of a critical curative treatment for cancer patients, supporting further investigation.
10.1200/JCO-25-02510
Apr 20 – Apr 27, 2026
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This expert opinion paper reviews the diagnostic and therapeutic management of various hematologic malignancies diagnosed during pregnancy, addressing the increasing global incidence in this population. The authors evaluate the safety and efficacy of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for conditions such as acute leukemia and lymphomas. It provides clinical guidance on balancing maternal oncological care with fetal safety, emphasizing that more women are now receiving adequate treatment without compromising pregnancy outcomes. The findings suggest that multidisciplinary approaches allow for expanded treatment possibilities, though specific numerical survival data were not provided in this qualitative expert consensus.
10.1200/JCO-25-02351
Apr 06 – Apr 13, 2026
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase I/II and pilot study evaluated the safety and efficacy of donor-derived IL15-activated cytokine-induced killer (IL15-CIK) cells in 53 adult and pediatric patients with high-risk leukemia following allogeneic hematopoietic stem-cell transplantation. Results demonstrated a 74% complete molecular remission rate in the preemptive treatment group and a five-year overall survival of 61% for preemptive and 71% for consolidation settings, with low rates of severe acute graft-versus-host disease (4% grade 3). The therapy shows significant clinical activity and a manageable safety profile, particularly when utilized as a preemptive or consolidation strategy rather than salvage therapy for advanced disease. These findings suggest that IL15-CIK monotherapy is a feasible post-transplant immunotherapeutic approach that could improve long-term outcomes for high-risk leukemia patients through optimized timing and patient selection.
10.1200/JCO-25-01966
Mar 23 – Mar 30, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study aimed to integrate genomic features into clinical decision-making for Chronic Myelomonocytic Leukemia (CMML), a myeloid neoplasm, by analyzing retrospective (3013 patients) and prospective (516 patients) cohorts. Researchers developed the international CMML Prognostic Scoring System (iCPSS), which identified nine molecular entities (p < .001) and five distinct prognostic groups (p < .001) for overall and leukemia-free survival, outperforming existing models, with 55% of patients reassigned to different risk groups. The iCPSS refined the optimal timing of allogeneic transplantation, changing strategies in 31% of cases and resulting in a significant gain-in-life expectancy (p < .001) for this cancer. This molecular-based system improves CMML classification, prognostication, and supports more effective, personalized clinical decision-making for cancer patients.
10.1200/JCO-25-02116